EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, INmune Bio's enterprise value is $186.56 Mil.
INmune Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.16 Mil. Therefore, INmune Bio's EV-to-Revenue for today is 1,203.61.
The historical rank and industry rank for INmune Bio's EV-to-Revenue or its related term are showing as below:
INMB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 157.36 Med: 510.59 Max: 28397.23
Current: 1203.61
During the past 8 years, the highest EV-to-Revenue of INmune Bio was 28397.23. The lowest was 157.36. And the median was 510.59.
INMB's EV-to-Revenue is ranked worse than 95.55% of 1033
companies
in the Biotechnology industry
Industry Median: 7.66
vs INMB: 1203.61
As of today (2024-04-28), INmune Bio's stock price is $11.29.
INmune Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, INmune Bio's PS Ratio for today is 1,254.44.
INmune Bio EV-to-Revenue Historical Data
The historical data trend for INmune Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of INmune Bio's EV-to-Revenue
For the Biotechnology subindustry, INmune Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where INmune Bio's EV-to-Revenue falls into.
INmune Bio's current Enterprise Value is $186.56 Mil.
INmune Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INmune Bio's share price for today is $11.29.
INmune Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INmune Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of INmune Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INMB has been successfully added to your 